Cantor Fitzgerald Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)

Research analysts at Cantor Fitzgerald started coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN) in a research report issued on Monday, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $57.00 price target on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 52.28% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ SUPN opened at $37.43 on Monday. The company has a market capitalization of $2.07 billion, a PE ratio of 34.98 and a beta of 0.90. The stock’s 50 day moving average price is $36.27 and its 200-day moving average price is $33.12. Supernus Pharmaceuticals has a twelve month low of $25.53 and a twelve month high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. The business’s revenue was up 14.2% on a year-over-year basis. As a group, research analysts expect that Supernus Pharmaceuticals will post 2.37 EPS for the current fiscal year.

Insider Activity

In other news, SVP Frank Mottola sold 15,000 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the transaction, the senior vice president now owns 8,200 shares of the company’s stock, valued at approximately $303,236. This represents a 64.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Georges Gemayel sold 14,213 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. This represents a 51.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 154,213 shares of company stock worth $5,660,180. 9.30% of the stock is owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp raised its position in shares of Supernus Pharmaceuticals by 0.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 425,387 shares of the specialty pharmaceutical company’s stock valued at $11,379,000 after buying an additional 2,427 shares in the last quarter. Commonwealth Equity Services LLC raised its position in Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock valued at $273,000 after purchasing an additional 350 shares in the last quarter. Rhumbline Advisers lifted its stake in Supernus Pharmaceuticals by 3.3% during the second quarter. Rhumbline Advisers now owns 180,274 shares of the specialty pharmaceutical company’s stock worth $4,822,000 after purchasing an additional 5,813 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 735,038 shares of the specialty pharmaceutical company’s stock worth $19,662,000 after purchasing an additional 87,200 shares in the last quarter. Finally, Candriam S.C.A. bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $3,795,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.